Drug perfusion device for resisting myocardial ischemia reperfusion injury

Abstract

The utility model discloses a medicine infusion device for resisting myocardial ischemia reperfusion injury, which comprises a shell, a second infusion hose is arranged in the shell, and the medicine infusion device further comprises a collecting mechanism. The collecting mechanism comprises a worm, a transmission rod, a worm gear and a collecting roller, the transmission rod is rotationally connected to the left surface of the interior of the shell, the worm gear is fixedly connected to the middle of the outer surface of the transmission rod, the collecting roller is fixedly connected to the right surface of the transmission rod, and the worm is rotationally connected to the interior of the shell; the right side of the collecting roller is wound with a second infusion hose, and the right surface of the shell is fixedly connected with a control switch set. According to the medicine infusion device for resisting the myocardial ischemia reperfusion injury, an infusion tube is collected and unfolded through the collecting mechanism, and therefore the medicine infusion device can resist the myocardial ischemia reperfusion injury; the length of the infusion tube can be freely adjusted according to needs, various different use requirements can be met, and a treatment site is tidier and more orderly.

Description

TECHNICAL FIELD

[0001] The utility model relates to medical equipment technical field, concretely is a kind of medicine perfusion device for anti myocardial ischemia reperfusion injury. BACKGROUND

[0002] Ischemic heart disease is one of the major causes of death worldwide, which brings great burden to individuals and society. Reconstructing coronary blood flow, relieving myocardial perfusion, reducing oxygen consumption, and maintaining the relative balance of coronary blood flow and myocardial demand are the main treatment methods for ischemic heart disease. Cell death is the final stage of various cells, and myocardial cells have limited proliferative capacity as a terminally differentiated cell. Therefore, controlling myocardial cell death is of great significance for the intervention of pathological cardiac remodeling. It is currently found that the main ways of myocardial cell death include apoptosis, pyroptosis and ferroptosis. Myocardial cell apoptosis is a kind of programmed cell death, and persistent myocardial cell apoptosis is considered to be an important factor in the occurrence of pathological cardiac remodeling. Therefore, blocking the apoptosis process of myocardial cells can effectively reduce pathological remodeling and heart failure. Studies have shown that apoptotic myocardial cells are detected in the boundary zone of infarct myocardium within a few hours to several days after infarction, and the use of pro-apoptotic inhibitors during early reperfusion can reduce infarct size.

[0003] Medicine perfusion is a treatment method of directly delivering medicine to a specific part of the body, mainly for internal diseases. When medicine perfusion is performed on patients with myocardial ischemia reperfusion injury, a medicine perfusion device for anti myocardial ischemia reperfusion injury is usually used for perfusion. The existing medicine perfusion device for anti myocardial ischemia reperfusion injury is connected to the patient's body through a transfusion tube, and the medicine in the medicine bottle is injected into the transfusion tube. The medicine perfusion is realized by the pressure difference between the air pressure and the internal blood vessels of the human body.

[0004] The length of the existing medicine perfusion device for anti myocardial ischemia reperfusion injury is fixed. When treatment is performed in a hospital, there are often many instruments, pipelines and lines. The transfusion tube of the medicine perfusion device for anti myocardial ischemia reperfusion injury has a fixed length, which can make the already chaotic medical devices more chaotic, and it is difficult to adapt to different use requirements. Therefore, we propose a medicine perfusion device for anti myocardial ischemia reperfusion injury. INVENTION CONTENTS

[0005] The technical problem to be solved by the utility model is to overcome the defects of the prior art, and provide a medicine perfusion device for anti myocardial ischemia reperfusion injury. The transfusion tube is bunched and unfolded by the bunching mechanism. The length of the transfusion tube can be adjusted freely according to the needs. It can adapt to various different use requirements, make the treatment site more tidy and orderly, and effectively solve the problems in the background art.

[0006] In order to achieve the above object, the utility model provides the following technical scheme: a kind of drug perfusion device for anti myocardial ischemia reperfusion injury, including shell, the inside of the shell is equipped with infusion hose two, it is characterized by: still including collection mechanism;

[0007] Collection mechanism: including worm, transmission rod, worm wheel and collection roller, the inside left surface of shell is rotatably connected with transmission rod, the middle part of the outer surface of transmission rod is fixedly connected with worm wheel, the right surface of transmission rod is fixedly connected with collection roller, the inside of shell is rotatably connected with worm, worm is meshed with worm wheel;

[0008] Wherein: the right side of the collection roller is wound with infusion hose two, by collection mechanism, infusion tube is bunched and unfolded, the length of infusion tube can be adjusted freely according to needs, can adapt to various different use demands, make treatment site more neat and orderly.

[0009] Further, the right surface of the shell is fixedly connected with the control switch group, the input end of the control switch group is electrically connected with the external power supply, the control motor and the infusion pump are started.

[0010] Further, the rear surface of the inside of the shell is fixedly connected with the motor, the output shaft of the motor is fixedly connected with the rear end of the worm, the input end of the motor is electrically connected with the output end of the control switch group, and the driving force is provided.

[0011] Further, the right surface of the inside of the shell is fixedly connected with the infusion pump, and the input end of the infusion pump is electrically connected with the output end of the control switch group.

[0012] Further, the inside of the collection roller is fixedly connected with the fixed infusion tube, the right side of the fixed infusion tube is rotatably connected with the infusion hose one through the rotary joint, the middle part of the infusion hose one is fixedly connected in the peristaltic pump cavity inside the infusion pump, the fixed infusion tube is communicated with the infusion hose two, and the medicine is conveyed.

[0013] Further, the upper end of the infusion hose one is fixedly connected with the liquid inlet, and the upper end of the infusion hose one is connected with the pressure stabilizing tube, and the right end of the pressure stabilizing tube is fixedly connected with the air filter screen.

[0014] Further, the inside lower surface and the outside lower surface of the shell are fixedly connected with the limiting ring, the infusion hose two is slidably connected with the inner surfaces of the two limiting rings respectively, and the lower end of the infusion hose two is fixedly connected with the liquid outlet.

[0015] Compared with the prior art, the utility model has the following advantages:

[0016] Through the bunching mechanism, the infusion tube is bunched and unfolded by using the motor to drive the bunching roller, the length of the infusion tube can be adjusted freely according to the requirement, various different use requirements can be adapted, and the treatment site is more tidy and orderly. BRIEF DESCRIPTION OF DRAWINGS

[0017] Fig. 1 It is a structure schematic diagram of the utility model;

[0018] Fig. 2 It is a structure schematic diagram of the utility model.

[0019] In the drawing: 1 shell, 2 liquid inlet, 3 pressure stabilizing tube, 4 control switch group, 5 liquid outlet, 6 bunching mechanism, 61 worm, 62 transmission rod, 63 worm wheel, 64 bunching roller, 7 motor, 8 infusion hose one, 9 infusion pump, 10 rotary joint, 11 infusion hose two, 12 limiting ring, 13 fixed infusion tube. DETAILED DESCRIPTION

[0020] The technical solutions in the embodiments of the utility model will be clearly and completely described below with reference to the drawings in the embodiments of the utility model. Obviously, the described embodiments are only part of the embodiments of the utility model, not all the embodiments. Based on the embodiments in the utility model, all other embodiments obtained by those skilled in the art without creative labor belong to the protection scope of the utility model.

[0021] Please refer to Figs. 1-2 The embodiment provides a technical scheme: a drug perfusion device for resisting myocardial ischemia-reperfusion injury, which comprises a shell 1, the inside of the shell 1 is provided with an infusion hose two 11, the right surface of the shell 1 is fixedly connected with a control switch group 4, the input end of the control switch group 4 is electrically connected with an external power supply, the inside right surface of the shell 1 is fixedly connected with an infusion pump 9, the input end of the infusion pump 9 is electrically connected with the output end of the control switch group 4, and the device further comprises a bunching mechanism 6.

[0022] The bunching mechanism 6 comprises a worm 61, a transmission rod 62, a worm wheel 63 and a bunching roller 64, the transmission rod 62 is rotationally connected to the inside left surface of the shell 1, the outer surface middle part of the transmission rod 62 is fixedly connected with the worm wheel 63, the right surface of the transmission rod 62 is fixedly connected with the bunching roller 64, the inside of the shell 1 is rotationally connected with the worm 61, the worm 61 is meshingly connected with the worm wheel 63, the inside rear surface of the shell 1 is fixedly connected with a motor 7, the output shaft of the motor 7 is fixedly connected with the rear end of the worm 61, the input end of the motor 7 is electrically connected with the output end of the control switch group 4, the control switch group 4 is operated, the motor 7 is started, the motor 7 output shaft rotates to drive the worm 61 to rotate, the worm wheel 63 is rotated to drive the transmission rod 62 to rotate, the bunching roller 64 is rotated to pull outwards the infusion hose two 11, when the infusion hose two 11 is elongated to a proper length, the motor 7 is turned off.

[0023] Wherein: the right side of the convergence roller 64 is wound with infusion hose two 11, the inner lower surface and the outer lower surface of the shell 1 are fixedly connected with limiting rings 12, the infusion hose two 11 is slidably connected with the inner surfaces of the two limiting rings 12 respectively, the lower end of the infusion hose two 11 is fixedly connected with the liquid outlet 5, the inside of the convergence roller 64 is fixedly connected with a fixed infusion tube 13, the right side of the fixed infusion tube 13 is rotatably connected with an infusion hose one 8 through a rotary joint 10, the middle part of the infusion hose one 8 is fixedly connected in a peristaltic pump cavity in the inside of an infusion pump 9, the central axis of the rotary joint 10 coincides with the central axis of the convergence roller 64, the fixed infusion tube 13 is communicated with the infusion hose two 11, the operation control switch group 4 is opened, the infusion pump 9 is opened, the infusion pump 9 pressurizes the infusion hose one 8, so that the medicine is transported in the perfusion device, the upper end of the infusion hose one 8 is fixedly connected with the liquid inlet 2, the upper end of the infusion hose one 8 is connected with a pressure stabilizing tube 3 in series, the right end of the pressure stabilizing tube 3 is fixedly connected with an air filter screen, the medicine is communicated with the liquid inlet 2, the medicine is discharged from the liquid outlet 5 through the liquid inlet 2, the infusion hose one 8, the infusion hose two 11 and the liquid outlet 5, the liquid outlet 5 is communicated with an external infusion interface, and the medicine perfusion is completed.

[0024] The working principle of the medicine perfusion device for resisting myocardial ischemia-reperfusion injury is as follows: when the medicine perfusion device for resisting myocardial ischemia-reperfusion injury is used for medicine perfusion, the medicine is communicated with the liquid inlet 2, the medicine is discharged from the liquid outlet 5 through the liquid inlet 2, the infusion hose one 8, the infusion hose two 11 and the liquid outlet 5, the operation control switch group 4 is opened, the infusion pump 9 is opened, the infusion pump 9 pressurizes the infusion hose one 8, so that the medicine is transported in the perfusion device, when the length of the infusion tube needs to be adjusted, the operation control switch group 4 is started, the motor 7 is started, the output shaft of the motor 7 rotates to drive the worm 61 to rotate, the worm gear 63 is rotated to drive the transmission rod 62 to rotate, the convergence roller 64 is rotated to pull out the infusion hose two 11 outward, when the infusion hose two 11 is elongated to a proper length, the motor 7 is closed, the liquid outlet 5 is communicated with the external infusion interface, and the medicine perfusion is completed.

[0025] It is worth noting that the motor 7 disclosed in the above embodiment is AKM2G-21E, the infusion pump 9 is KL-8052N, and the control switch group 4 is provided with control buttons corresponding to the motor 7 and the infusion pump 9 and used for controlling the switches of the motor 7 and the infusion pump 9.

[0026] Research finds that: in the treatment of myocardial ischemia and other heart diseases, ligustrazine (TMP) is one of the functional components of Chinese medicine chuanxiong, TMP has been proved to have various pharmacological properties, and is used for the treatment of coronary heart disease and has excellent treatment effect.

[0027] Chuanxiong is the dried stem and root of *Ligusticum chuanxiong* Hort., a plant in the Apiaceae family. Originally named "Xiongxiong," it was first recorded in the *Shennong Bencao Jing* (Shennong's Classic of Materia Medica), classified as a superior herb. The book describes it as having a pungent and warm flavor, and being non-toxic. It is used to treat stroke affecting the brain, headache, cold-induced numbness and muscle spasms, metal wounds, and amenorrhea in women, indicating its effects of promoting blood circulation, regulating qi, dispelling wind, and relieving pain. The *Compendium of Materia Medica* states: "(Xiongxiong) that comes from Guanzhong is called Jingxiong, also known as Xixiong."

[0028] The variety from Sichuan is called Chuanxiong; the variety from Tiantai is called Taixiong; and the variety from Jiangnan is called Fuxiong, all named after their place of origin. Kou Zongshi of the Song Dynasty believed that "the best quality Chuanxiong is the large, white-colored, non-oily variety from Sichuan, which has a slightly spicy and sweet taste when chewed." Therefore, later generations considered Chuanxiong a genuine medicinal material. The *Mingyi Bielu* states that Chuanxiong has the effects of "removing coldness in the brain, wind-cold in the face, excessive tearing, excessive spitting, dizziness, various cold symptoms, abdominal pain, sudden and severe swelling and pain, rib pain, and warming the middle burner and relieving internal cold," indicating that ancient physicians had already discovered its effectiveness in treating heart diseases. Chuanxiong is pungent and warm in nature, entering the liver, gallbladder, and pericardium meridians, and has the effects of promoting qi and blood circulation, dispelling wind, and relieving pain.

[0029] TMP can improve ischemia-reperfusion injury and protect myocardial cells by regulating the balance of tissue oxidation and antioxidant, scavenging oxygen free radicals, increasing Ca2+-ATPase activity, inhibiting intracellular calcium overload, and inhibiting inflammatory response. Many experiments and clinical applications have confirmed that TMP has the effect of promoting blood circulation to remove blood stasis, has obvious effect in the treatment of cardiovascular and cerebrovascular diseases, and can inhibit myocardial cell apoptosis. The activation of PI3K / Akt can promote cell survival and recruit anti-apoptotic pathways during reperfusion. Yang et al. proved that TMP exerts cardioprotective effects by regulating the PI3K / Akt / GSK-3β pathway. Their study also showed that TMP reduces isoproterenol-induced myocardial injury in AMI rats by regulating inflammation (IL-1β, IL-6, and TNF-α) and oxidative stress. NO is an important regulator of apoptosis, which can induce and prevent cell apoptosis. The basal level of NO produced by eNOS can protect myocardial cells from apoptosis. TMP exerts anti-apoptotic and cardiovascular effects by activating eNOS and increasing NO production. A study found that TMP (5 and 10 mg / kg, intravenous injection) can attenuate oxidative stress and prevent MIRI-induced apoptosis by activating the antioxidant effect of HO-1. TMP also protects the cardiovascular system through other mechanisms. TMP has strong anti-endoplasmic reticulum (ER) stress capacity. Mak et al. pointed out that TMP (100 μM) has strong anti-ER stress capacity, and TMP normalizes sEH / EET through this capacity and has a protective effect on endothelial function in the coronary artery. Large conductance calcium-activated potassium channels (BKCa) are encoded by the Kcnma1 gene. The expression and activity of BKCa are associated with several cardiovascular, muscle, and nervous system defects, making it a key therapeutic target. A study showed that TMP (100 μM) maintained BKCa β1 protein levels and restored BKCa current in porcine coronary artery smooth muscle cells by inhibiting endoplasmic reticulum stress, while improving BKCa-mediated coronary artery dilation. In addition, TMP can treat ischemic heart disease by reducing cardiac ischemia-induced acid-sensing ion channel current. Ji et al. pointed out that TMP inhibits isoproterenol-induced cardiomyocyte hypertrophy in neonatal rats by reducing the expression of Ca+N. It can be seen that TMP has excellent therapeutic effect on MIRI.

[0030] Studies have shown that m6A RNA methylation plays a key regulatory role in myocardial ischemia reperfusion and heart regeneration. KE et al. found that the demethylase Alkbh5 can erase the m6A methylation modification of its downstream target effector Yes-associated protein, thereby alleviating the process of hypoxia / reoxygenation-induced myocardial cell apoptosis. This suggests that intervention of m6A modification of RNA may become an important therapeutic target for ischemic heart disease. Ligustrazine can cause changes in m6A in myocardial ischemia reperfusion injury. Therefore, it is inferred that ligustrazine regulates myocardial ischemia reperfusion injury through m6A modification.

[0031] In summary, perfusion of ligustrazine and other drugs through the device has important therapeutic and research significance for the treatment of myocardial ischemia reperfusion injury. Moreover, with the aging of the population, ischemic heart disease has a greater and greater impact on people's health, and cardiac ischemia reperfusion, as an inevitable pathophysiological process in the development and treatment of ischemic heart disease, poses a huge challenge to the survival and prognosis of patients. Therefore, the development of more types of perfusion treatment drugs through research on the significance of protecting cardiac function in MIRI, the main components of traditional Chinese medicine and the specific mechanism of action, has great significance for the treatment and prognosis of diseases.

[0032] The above is only an embodiment of the present application, and does not limit the patent range of the present application, and any equivalent structure or equivalent process conversion using the content of the present application specification and drawings, or direct or indirect application in other related technical fields, are also included in the patent protection range of the present application.

Claims

1. A medicine perfusion device for anti-myocardial ischemia-reperfusion injury, comprising a shell (1), the inside of the shell (1) is provided with a transfusion hose two (11), characterized in that: Also include the collection mechanism (6); The collection mechanism (6) comprises a worm (61), a transmission rod (62), a worm wheel (63) and a collection roller (64), the transmission rod (62) is rotatably connected to the inner left surface of the shell (1), the outer surface of the transmission rod (62) is fixedly connected with the worm wheel (63), the right surface of the transmission rod (62) is fixedly connected with the collection roller (64), the worm (61) is rotatably connected in the shell (1), the worm (61) is meshed with the worm wheel (63); Wherein: the right side of the collection roller (64) is wound with infusion hose two (11).

2. The pharmaceutical perfusion device for anti-myocardial ischemia-reperfusion injury according to claim 1, characterized in that: The right surface of the shell (1) is fixedly connected with the control switch group (4), and the input end of the control switch group (4) is electrically connected with the external power supply.

3. The pharmaceutical perfusion device for anti-myocardial ischemia-reperfusion injury according to claim 2, characterized in that: The rear surface of the shell (1) is fixedly connected with the motor (7), the output shaft of the motor (7) is fixedly connected with the rear end of the worm (61), and the input end of the motor (7) is electrically connected with the output end of the control switch group (4).

4. The pharmaceutical perfusion device for anti-myocardial ischemia-reperfusion injury according to claim 2, characterized in that: The right surface of the shell (1) is fixedly connected with the infusion pump (9), and the input end of the infusion pump (9) is electrically connected with the output end of the control switch group (4).

5. The pharmaceutical perfusion device for anti-myocardial ischemia-reperfusion injury according to claim 4, characterized in that: The inside of the collection roller (64) is fixedly connected with the fixed infusion tube (13), the right side of the fixed infusion tube (13) is rotatably connected with the infusion hose one (8) through the rotary joint (10), the middle part of the infusion hose one (8) is fixedly connected in the peristaltic pump cavity inside the infusion pump (9), and the fixed infusion tube (13) is communicated with the infusion hose two (11).

6. The pharmaceutical perfusion device for anti-myocardial ischemia-reperfusion injury according to claim 5, characterized in that: The upper end of the infusion hose one (8) is fixedly connected with the liquid inlet (2), the upper end of the infusion hose one (8) is connected with the stabilizing tube (3), and the right end of the stabilizing tube (3) is fixedly connected with the air filter screen.

7. The pharmaceutical perfusion device for anti-myocardial ischemia-reperfusion injury according to claim 1, characterized in that: The inner surface and the outer surface of the shell (1) are fixedly connected with the limiting ring (12), the infusion hose two (11) is slidably connected with the inner surface of the two limiting rings (12), and the lower end of the infusion hose two (11) is fixedly connected with the liquid outlet (5).

Images